Request Trial
18 July 2025VideosAmericasJohn Rearick, Dechert | Michael Penn, BlueRock Therapeutics | Mark Stewart, Merck | Paul Fleming, Seaport Therapeutics | Robin Weatherhead, Ventus Therapeutics

WATCH: Enabling success—mastering s112 in the new era of life sciences patents

Experts from Dechert, BlueRock Therapeutics, Merck, Seaport Therapeutics, and Ventus Therapeutics examine the impact of recent court rulings following Amgen v. Sanofi on broad genus claims within life sciences patents, as discussed at LSPN.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Sanofi suffers setback in insulin monopoly dispute
29 January 2026   A judge has allowed antitrust claims against the pharma giant to move forward, finding that it plausibly used bundled rebates and patent abuse to extend its insulin monopoly, though one allegation was dismissed.
Americas
Eli Lilly’s Mounjaro tops list of cyber squatter targets
28 January 2026   The rise of fake online stores selling counterfeit pharmaceuticals is driving a surge in domain name disputes, forcing major brands to defend revenue and reputation.
Americas
The quantum advantage: IP considerations for the next generation of life sciences innovation
27 January 2026   As quantum-enabled innovation accelerates, patentability will hinge on predictability, disclosure, and modality-specific claim drafting in an increasingly unforgiving enablement landscape, explain Ray Miller and Joseph Wolfe of DLA Piper


Editor's picks

The quantum advantage: IP considerations for the next generation of life sciences innovation
Americas
The quantum advantage: IP considerations for the next generation of life sciences innovation
27 January 2026

Editor's picks

Americas
The quantum advantage: IP considerations for the next generation of life sciences innovation
27 January 2026
Americas
Bayer enters COVID-19 vaccine row with three suits against major drugmakers
8 January 2026
Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025
Europe
Abbott appeals ‘baffling’ decision in glucose monitoring device feud
16 December 2025
Americas
Teva scrubs 200-plus Orange Book patents after FTC turns the screw
11 December 2025
Americas
US govt backs Hikma over ‘skinny label’ rules
9 December 2025

More features

Crowell adds tech partner with in-house and private practice expertise
Sanofi suffers setback in insulin monopoly dispute
Firm adds seven-lawyer team in second major merger
Eli Lilly’s Mounjaro tops list of cyber squatter targets
The quantum advantage: IP considerations for the next generation of life sciences innovation
Fed Circ overturns PTAB decision in $83.4m DNA case
Simpson Thacher adds ‘exemplary’ litigator with emerging tech expertise
AI is transforming top 100 innovators, shows index